Skip to main content
Clinical Trials/NCT06631365
NCT06631365
Recruiting
Phase 2

PrEPsmart Pilot: a Trial to Evaluate a Mobile App to Support the Safe and Effective Use of On-demand Pre-exposure Prophylaxis (PrEP) Among Sexual Minority Men in the US

Public Health Foundation Enterprises, Inc.1 site in 1 country60 target enrollmentOctober 2, 2023

Overview

Phase
Phase 2
Intervention
PrEPsmart mobile app
Conditions
HIV-1-infection
Sponsor
Public Health Foundation Enterprises, Inc.
Enrollment
60
Locations
1
Primary Endpoint
Acceptability of the PrEPsmart mobile app
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a pilot study to assess the feasibility, acceptability, and preliminary effectiveness of pre-exposure prophylaxis (PrEP)smart among cisgender sexual minority males (SMM) taking on-demand PrEP over a 6-month period.

Upon project completion, the investigators will have developed a highly innovative tool to support men who have sex with men (MSM) using on-demand PrEP ready for testing in a larger efficacy trial

Detailed Description

This study is designed to enroll a diverse population of English-speaking cisgender sexual minority males (SMM) in the United States. The study team will enroll up to 60 participants who are taking or are interested in taking on-demand pre-exposure prophylaxis (PrEP). Participants will be randomized 2:1 to receive (intervention arm) or not receive (control arm) the PrEPsmart app at enrollment. Participants will complete follow-up visits at 3 and 6 months. Participants newly starting 2-1-1 PrEP will be seen at the Bridge HIV clinic (prescribed group), while those already on PrEP may be seen at the clinic or complete visits virtually (non-prescribed group). Although no restrictions are put on the racial/ethnic make-up of the study participants, the site will strive to enroll at least 50% African American or Latino SMM into this study. The study will also strive to enroll at least 30% of participants who are newly starting or restarting 2-1-1 PrEP. Upon project completion, the study team will have developed a highly innovative tool to support men who have sex with men (MSM) using on-demand PrEP ready for testing in a larger efficacy trial.

Registry
clinicaltrials.gov
Start Date
October 2, 2023
End Date
April 1, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Cisgender-male who reports sex with persons assigned male at birth
  • Willing and able to provide written informed consent
  • HIV-uninfected by negative 4th generation HIV test during screening (prescribed group)
  • Documentation of negative HIV test within the last 3 months by outside laboratory OR evidence of PrEP prescription within the last 6 months based on medical records or pharmacy/provider communication
  • Owns an iOS or Android mobile phone with a camera and has private access to the internet
  • Able to understand, read, and speak English
  • Able to attend study visits at a local research site in San Francisco (Bridge HIV) (prescribed and non-prescribed groups) or virtual visits via a HIPAA-compliant teleconferencing platform (non-prescribed group)
  • Interested in starting or currently taking on-demand PrEP with TDF/FTC
  • Report having anal sex at least once a month and expecting to maintain at least this frequency of anal sex during study participation by self-report

Exclusion Criteria

  • Repeatedly reactive HIV test at screening or enrollment or self-reported reactive HIV test (prescribed group)
  • Signs or symptoms of acute HIV infection at screening or enrollment
  • Currently enrolled in another PrEP intervention study.
  • Unable to commit to study participation for the duration of the study
  • Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Arms & Interventions

PrEPsmart intervention (N=40)

Participants will be randomized in a 2:1 ratio to the intervention (N=40) For the pre-exposure prophylaxis (PrEP)smart intervention group, a study clinician will perform a medical history and limited physical exam to confirm eligibility to enroll in the study, a 4th generation rapid Human immunodeficiency virus (HIV) test will be performed, and labs drawn for creatinine, sexual transmitted infection (STI) testing (Neisseria gonorrhoeae/Chlamydia trachomatis (GC/CT)), syphilis), and hepatitis B testing. For participants newly starting 2-1-1 PrEP (PrEPsmart intervention group), study drug will be offered to participants to ensure that they will have access to PrEP during the study to be able to adequately test the app.

Intervention: PrEPsmart mobile app

PrEPsmart intervention (N=40)

Participants will be randomized in a 2:1 ratio to the intervention (N=40) For the pre-exposure prophylaxis (PrEP)smart intervention group, a study clinician will perform a medical history and limited physical exam to confirm eligibility to enroll in the study, a 4th generation rapid Human immunodeficiency virus (HIV) test will be performed, and labs drawn for creatinine, sexual transmitted infection (STI) testing (Neisseria gonorrhoeae/Chlamydia trachomatis (GC/CT)), syphilis), and hepatitis B testing. For participants newly starting 2-1-1 PrEP (PrEPsmart intervention group), study drug will be offered to participants to ensure that they will have access to PrEP during the study to be able to adequately test the app.

Intervention: Truvada

Outcomes

Primary Outcomes

Acceptability of the PrEPsmart mobile app

Time Frame: 6 months

Acceptability will be measured using the Client Satisfaction Questionnaire (CSQ-8) adapted for use in PrEPsmart pilot. The study team will also assess interest in future use of the app at study completion.

Usability of the PrEPsmart mobile app

Time Frame: 6 months

Usability will be measured using the System Usability Scale (SUS) adapted for use in PrEPsmart pilot. A score \>50 (out of 100) on the SUS indicates the app is acceptable.

Secondary Outcomes

  • To compare PrEP coverage of sex acts as measured by weekly urine tenofovir test strips among SMM in the PrEPsmart vs. control arms(6 months)
  • To compare switching of PrEP regimens among SMM in the PrEPsmart vs. control arms(6 months)
  • To compare rates of PrEP discontinuation among SMM in the PrEPsmart vs. control arm(6 months)
  • Elicit feedback on areas for improvement for PrEPsmart to guide further app refinement(6 months)

Study Sites (1)

Loading locations...

Similar Trials